Literature DB >> 2044050

Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas.

K Tauchi1, K Kakudo, T Machimura, H Makuuchi, T Mitomi.   

Abstract

A total of 63 surgically resected esophageal carcinomas (including 49 superficial esophageal carcinomas) and histologically normal tissue adjacent to the superficial carcinoma (nontumorous epithelium) were examined immunohistochemically for the blood group antigens (BGA) A, B, H, Lewisa, Lewisb, Lewisx, and Lewisy. Deletion of an expected A, B or H antigen occurred in 12 (24.5%) of the 49 superficial carcinomas and three (21.4%) of the 14 advanced carcinomas. Incompatible expression of an unexpected A or B antigens occurred in only one case (1.6%) in the carcinoma. In the clinicopathologic study, there was a significant correlation between immunoreactivity of Lewisa and depth of cancer invasion (chi-square test, P less than 0.05). In the superficial carcinoma, there were significant correlations between immunoreactivity of Lewisx and lymph node status (chi-square test, P less than 0.05), immunoreactivity of Lewisy and prognosis (Z test, P less than 0.05), and incompatible expression of Lewisb for tumor against nontumorous epithelium and histologic variation (chi-square test, P less than 0.01). The functional significance of alternations in BGA expression that may be associated with oncogenesis is not clear. However, immunohistochemical determination of BGA may be a more advantageous marker to predict the patient's clinical course in superficial esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044050     DOI: 10.1002/1097-0142(19910615)67:12<3042::aid-cncr2820671219>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.

Authors:  Jennifer A Westwood; Mark J Smyth; Michele W L Teng; Maria Moeller; Joseph A Trapani; Andrew M Scott; Fiona E Smyth; Glenn A Cartwright; Barbara E Power; Dirk Hönemann; H Miles Prince; Phillip K Darcy; Michael H Kershaw
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

2.  A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China.

Authors:  Miao-Zhen Qiu; Dong-Sheng Zhang; Dan-Yun Ruan; Hui-Yan Luo; Zhi-Qiang Wang; Zhi-Wei Zhou; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu
Journal:  Med Oncol       Date:  2010-11-04       Impact factor: 3.064

3.  A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma.

Authors:  Penelope M Drake; Birgit Schilling; Richard K Niles; Miles Braten; Eric Johansen; Haichuan Liu; Michael Lerch; Dylan J Sorensen; Bensheng Li; Simon Allen; Steven C Hall; H Ewa Witkowska; Fred E Regnier; Bradford W Gibson; Susan J Fisher
Journal:  Anal Biochem       Date:  2010-08-10       Impact factor: 3.365

4.  The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: a retrospective study from China.

Authors:  Peng Sun; Cui Chen; Fei Zhang; Xin An; Xiu-Yue Li; Yu-Hong Li; Zhi-Hua Zhu; Feng-Hua Wang
Journal:  Tumour Biol       Date:  2014-04-27

Review 5.  Sweetening the pot: adding glycosylation to the biomarker discovery equation.

Authors:  Penelope M Drake; Wonryeon Cho; Bensheng Li; Akraporn Prakobphol; Eric Johansen; N Leigh Anderson; Fred E Regnier; Bradford W Gibson; Susan J Fisher
Journal:  Clin Chem       Date:  2009-12-03       Impact factor: 8.327

6.  High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.

Authors:  Zahra Madjd; Tina Parsons; Nicholas F S Watson; Ian Spendlove; Ian Ellis; Lindy G Durrant
Journal:  Breast Cancer Res       Date:  2005-07-28       Impact factor: 6.466

7.  Prognostic value of ABO blood group in patients with surgically resected colon cancer.

Authors:  X Cao; Z-S Wen; Y-J Sun; Y Li; L Zhang; Y-J Han
Journal:  Br J Cancer       Date:  2014-06-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.